Navigation Links
Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
Date:10/3/2011

SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 2011 BioCentury Newsmakers in the Biotech Industry conference on Friday, October 21 at 11:00 AM Eastern time.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of the presentation will be available at the same location for 30 days following the conference.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients 18 years of age and older with Clostridium difficile-associated diarrhea (CDAD). Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

 

 

 


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Valeant Pharmaceuticals International, Inc. (NYSE: ... positive results from a Phase 3, multicenter double-blind, ... and efficacy of IDP-118 (halobetasol propionate and tazarotene) ... Within the Phase 3 study of ... IDP-118 showed statistical significance to vehicle with a ...
(Date:12/8/2016)... , Dec. 8, 2016 True ... that brings leading-edge laboratory services and management expertise ... States , allowing more doctors and patients ... care management solutions. Logo - ... Hospital systems, under pressure to contain costs, ...
(Date:12/8/2016)... -- Information products and services provider Elsevier ... , the world,s largest abstract and citation database of peer-reviewed literature, ... from over 5,000 publishers. The new set of metrics will improve ... when to adjust a journal,s editorial strategy. ... , , CiteScore ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , Ginger ... Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport ... attorneys from the firm’s global Life Sciences & Medical Technology Group have been featured ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
(Date:12/8/2016)... ... ... Vida Health, the digital health platform that pairs individuals with ... . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect Ventures. Vida ... are managing chronic conditions or simply want to improve their health. Canvas ...
(Date:12/8/2016)... ... , ... Coppin Insurance Agency, an insurance and financial planning firm based in ... area, is embarking on a charity drive with the goal of providing support and ... Food Bank of Southwest Florida works to provide fresh and nutritious food free of ...
(Date:12/7/2016)... Washington,DC (PRWEB) , ... December 07, 2016 , ... ... Forum (NYLF): Medicine will have the unique opportunity to get hands-on experience ... gives high school students an immersive experience to gain invaluable, real-life medical skills ...
Breaking Medicine News(10 mins):